Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Purchases $28,842,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bros. Advisors Lp Baker purchased 655,500 shares of the stock in a transaction dated Monday, June 30th. The stock was purchased at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the completion of the purchase, the director directly owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. The trade was a 12.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kymera Therapeutics Stock Up 0.6%

Kymera Therapeutics stock traded up $0.28 during trading on Thursday, reaching $44.81. The stock had a trading volume of 240,486 shares, compared to its average volume of 632,626. Kymera Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $53.27. The business has a 50 day moving average price of $38.00 and a 200 day moving average price of $35.89. The stock has a market cap of $2.92 billion, a PE ratio of -14.45 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. Kymera Therapeutics's quarterly revenue was up 114.6% on a year-over-year basis. During the same period last year, the firm earned ($0.69) earnings per share. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Stifel Nicolaus started coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 price objective on the stock. Wells Fargo & Company reduced their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a report on Thursday, June 26th. Oppenheimer reissued an "outperform" rating and issued a $53.00 price objective (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective (up from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $59.11.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYMR. Wellington Management Group LLP increased its stake in Kymera Therapeutics by 13.0% in the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock valued at $164,134,000 after purchasing an additional 689,547 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after buying an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Kymera Therapeutics in the 4th quarter valued at $23,856,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after buying an additional 491,737 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $17,098,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.